雌激素-孕激素与孕激素用于子宫内膜异位症的管理
Endometriosis is characterized by frequent recurrences of symptoms and lesions even after extirpative surgery. Because medical therapies control but do not cure the disease, long periods of pharmacologic management may be needed until pregnancy desire or, sometimes, physiologic m…
要点
- 雌激素-孕激素和孕激素可长期用于子宫内膜异位症,至少三分之二有症状女性疼痛缓解。
- 连续使用雌激素-孕激素时应解释个体化调整方案以提高依从性。
- 孕激素建议用于对雌激素-孕激素无反应或不耐受者及有性交痛和/或深部病灶者。
核心结论
- 雌激素-孕激素和孕激素是仅有的具有允许长期使用安全性、耐受性和成本特征的激素药物,可控制但不能治愈子宫内膜异位症。
研究设计与样本
- 原文未报告研究设计。
主要发现
- 至少三分之二有症状女性疼痛缓解并达到健康相关生活质量的 appreciable 改善。
- 孕激素抵抗可能导致剩余三分之一无反应。
- 所有复方对痛经显示相似效果,与孕激素类型无关。
- 雌激素-孕激素和孕激素降低术后子宫内膜瘤复发率,并对子宫内膜异位症相关上皮性卵巢癌风险显示保护作用。
关键数值与推荐
- 应选择雌激素剂量尽可能低的雌激素-孕激素,以结合最佳病灶抑制和血栓风险限制。
- 连续使用雌激素-孕激素时,应解释个体化调整方案以提高依从性。
- 孕激素不显著增加血栓风险,通常可在雌激素禁忌时使用。
临床怎么用
- 孕激素建议用于对雌激素-孕激素无反应或表现不耐受的女性以及有性交痛和/或深部病灶者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endometriosis is characterized by frequent recurrences of symptoms and lesions even after extirpative surgery. Because medical therapies control but do not cure the disease, long periods of pharmacologic management may be needed until pregnancy desire or, sometimes, physiologic menopause. Hormonal drugs suppress ovulation and menstruation and have similar beneficial effects against pain. However, only estrogen-progestins and progestins have safety/tolerability/cost profiles that allow long-term use. These compounds induce atrophy of eutopic and ectopic endometrium, have antiinflammatory and proapoptotic properties, and can be delivered via different modalities, including oral, transdermal, subcutaneous, intramuscular, vaginal, and intrauterine routes. At least two-thirds of symptomatic women are relieved from pain and achieve appreciable improvements in health-related quality of life. Progesterone resistance may cause nonresponse in the remaining one-third. When using estrogen-progestins continuously, individualized, tailored cycling should be explained to improve compliance. All combinations demonstrated a similar effect on dysmenorrhea, independently from progestin type. Estrogen-progestins with the lowest possible estrogen dose should be chosen to combine optimal lesion suppression and thrombotic risk limitation. Progestins should be suggested in women who do not respond or manifest intolerance to estrogen-progestins and in those with dyspareunia and/or deep lesions. Progestins do not increase significantly the thrombotic risk and generally may be used when estrogens are contraindicated. Estrogen-progestins and progestins reduce the incidence of postoperative endometrioma recurrence and show a protective effect against endometriosis-associated epithelial ovarian cancer risk.
引用
- Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016. PMID: 27817837. doi:10.1016/j.fertnstert.2016.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。